Last year, Eli Lilly and Co generated 11.54B USD for its biggest-performing segment, Diabetes-Mounjaro. The U.S. made the largest contribution, accounting for 43.48B USD last year. For the latest quarter, Eli Lilly and Co reported the revenue of 9.94B USD for the period ending 2026-06-30, which came from the top-performing segment, Diabetes-Mounjaro. U.S. contributed the highest revenue, at 14.41B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Diabetes-Mounjaro

Oncology-Verzenio

Diabetes-Trulicity

Diabetes-Zepbound

Diabetes-Jardiance

Immunology-Taltz

Diabetes-Humalog

Oncology-Other Oncology

Oncology-Cyramza

Immunology-Olumiant

Diabetes-Humulin

Other-Other

Neuroscience-Emgality

Diabetes-Basaglar

Oncology-Erbitux

Oncology-Tyvyt

Diabetes-Other Diabetes

Neuroscience-Other Neuroscience

Immunology-Other Immunology

Neuroscience-Zyprexa

Diabetes-Baqsimi

Other-Forteo

Other-Cialis

Oncology-Alimta

Other-COVID-19 Antibodies

Neuroscience-Cymbalta

Diabetes-Trajenta

Other Bamlanivimab

Endocrinology-Trulicity

Endocrinology-Humalog

Endocrinology-Forteo

Endocrinology-Humulin

Endocrinology-Basaglar

Endocrinology-Jardiance

Endocrinology-Trajenta

Endocrinology-Olumiant

Neuroscience-Strattera

Product

Collaborationand Other Revenue

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Diabetes-Mounjaro

11.54B(25.62%)

5.16B(15.13%)

482.50M(1.69%)

--(--)

Oncology-Verzenio

5.31B(11.78%)

3.86B(11.32%)

2.48B(8.70%)

1.35B(4.77%)

912.60M(3.72%)

579.70M(2.60%)

--(--)

Diabetes-Trulicity

5.25B(11.66%)

7.13B(20.90%)

7.44B(26.07%)

6.47B(22.85%)

5.07B(20.65%)

--(--)

Diabetes-Zepbound

4.93B(10.94%)

175.80M(0.52%)

--(--)

Diabetes-Jardiance

3.34B(7.42%)

2.74B(8.04%)

2.07B(7.24%)

1.49B(5.26%)

1.15B(4.70%)

--(--)

Immunology-Taltz

3.26B(7.24%)

2.76B(8.09%)

2.48B(8.70%)

2.21B(7.81%)

1.79B(7.29%)

1.37B(6.12%)

--(--)

Diabetes-Humalog

2.32B(5.16%)

1.66B(4.87%)

2.06B(7.22%)

2.45B(8.66%)

2.63B(10.70%)

--(--)

Oncology-Other Oncology

1.32B(2.93%)

612.90M(1.80%)

423.80M(1.48%)

330.80M(1.17%)

507.60M(2.07%)

450.30M(2.02%)

--(--)

Oncology-Cyramza

973.20M(2.16%)

974.70M(2.86%)

971.40M(3.40%)

1.03B(3.65%)

1.03B(4.21%)

925.20M(4.15%)

--(--)

Immunology-Olumiant

957.40M(2.13%)

922.70M(2.70%)

830.50M(2.91%)

1.12B(3.94%)

638.80M(2.60%)

--(--)

Diabetes-Humulin

917.10M(2.04%)

852.10M(2.50%)

1.02B(3.57%)

1.22B(4.32%)

1.26B(5.13%)

--(--)

Other-Other

903.00M(2.00%)

207.60M(0.61%)

295.50M(1.04%)

370.00M(1.31%)

568.20M(2.32%)

483.90M(2.17%)

--(--)

Neuroscience-Emgality

870.40M(1.93%)

678.20M(1.99%)

650.90M(2.28%)

577.20M(2.04%)

362.90M(1.48%)

162.60M(0.73%)

--(--)

Diabetes-Basaglar

676.90M(1.50%)

728.30M(2.13%)

760.40M(2.66%)

892.50M(3.15%)

1.12B(4.58%)

--(--)

Oncology-Erbitux

627.40M(1.39%)

596.50M(1.75%)

566.50M(1.98%)

548.20M(1.94%)

536.40M(2.19%)

543.30M(2.43%)

--(--)

Oncology-Tyvyt

526.00M(1.17%)

393.40M(1.15%)

293.30M(1.03%)

418.10M(1.48%)

--(--)

Diabetes-Other Diabetes

512.70M(1.14%)

530.20M(1.55%)

636.20M(2.23%)

284.80M(1.01%)

244.00M(0.99%)

--(--)

Neuroscience-Other Neuroscience

486.70M(1.08%)

505.50M(1.48%)

275.10M(0.96%)

309.50M(1.09%)

294.10M(1.20%)

173.80M(0.78%)

--(--)

Immunology-Other Immunology

175.10M(0.39%)

115.20M(0.34%)

32.10M(0.11%)

32.90M(0.12%)

34.60M(0.14%)

426.90M(1.91%)

--(--)

Neuroscience-Zyprexa

116.30M(0.26%)

1.69B(4.97%)

336.90M(1.18%)

430.30M(1.52%)

406.60M(1.66%)

418.60M(1.88%)

--(--)

Diabetes-Baqsimi

29.20M(0.06%)

677.60M(1.99%)

--(--)

Other-Forteo

--(--)

533.20M(1.56%)

613.10M(2.15%)

801.90M(2.83%)

1.05B(4.26%)

--(--)

Other-Cialis

--(--)

381.40M(1.12%)

587.30M(2.06%)

718.50M(2.54%)

607.20M(2.47%)

890.50M(3.99%)

--(--)

Oncology-Alimta

--(--)

217.50M(0.64%)

927.70M(3.25%)

2.06B(7.28%)

2.33B(9.49%)

2.12B(9.48%)

--(--)

Other-COVID-19 Antibodies

--(--)

2.02B(7.09%)

2.24B(7.91%)

--(--)

Neuroscience-Cymbalta

--(--)

283.30M(0.99%)

581.50M(2.05%)

767.70M(3.13%)

725.40M(3.25%)

--(--)

Diabetes-Trajenta

--(--)

372.50M(1.32%)

358.60M(1.46%)

--(--)

Other Bamlanivimab

--(--)

871.20M(3.55%)

--(--)

Endocrinology-Trulicity

--(--)

4.13B(18.49%)

--(--)

Endocrinology-Humalog

--(--)

2.82B(12.64%)

--(--)

Endocrinology-Forteo

--(--)

1.40B(6.29%)

--(--)

Endocrinology-Humulin

--(--)

1.29B(5.78%)

--(--)

Endocrinology-Basaglar

--(--)

1.11B(4.98%)

--(--)

Endocrinology-Jardiance

--(--)

944.20M(4.23%)

--(--)

Endocrinology-Trajenta

--(--)

590.60M(2.65%)

--(--)

Endocrinology-Olumiant

--(--)

523.80M(2.35%)

--(--)

Neuroscience-Strattera

--(--)

242.50M(1.09%)

--(--)

Product

--(--)

22.93B(93.37%)

Collaborationand Other Revenue

--(--)

1.63B(6.63%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

U.S.

Europe

Other foreign countries

Japan

China

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

U.S.

43.48B(66.71%)

30.38B(67.44%)

21.79B(63.86%)

18.19B(63.73%)

16.81B(59.36%)

14.23B(57.98%)

12.72B(57.00%)

12.39B(57.65%)

11.41B(57.15%)

11.51B(54.22%)

10.10B(50.59%)

9.13B(46.57%)

12.89B(55.77%)

12.31B(54.47%)

12.98B(53.43%)

Europe

11.56B(17.73%)

6.92B(15.36%)

6.17B(18.09%)

4.30B(15.06%)

4.78B(16.87%)

4.19B(17.06%)

3.77B(16.87%)

3.66B(17.04%)

3.39B(16.98%)

3.77B(17.76%)

3.94B(19.76%)

4.51B(22.98%)

4.34B(18.77%)

4.26B(18.85%)

5.29B(21.79%)

Other foreign countries

6.06B(9.29%)

4.27B(9.48%)

2.95B(8.63%)

2.85B(9.99%)

2.70B(9.54%)

2.42B(9.87%)

3.28B(14.71%)

3.03B(14.10%)

2.83B(14.17%)

3.62B(17.04%)

3.88B(19.46%)

3.95B(20.13%)

3.82B(16.53%)

3.78B(16.74%)

3.91B(16.12%)

Japan

2.13B(3.27%)

1.81B(4.03%)

1.67B(4.90%)

1.75B(6.12%)

2.37B(8.36%)

2.58B(10.53%)

2.55B(11.41%)

2.41B(11.20%)

2.34B(11.71%)

2.33B(10.98%)

2.03B(10.19%)

2.03B(10.33%)

2.06B(8.93%)

2.25B(9.94%)

2.10B(8.66%)

China

1.95B(2.99%)

1.66B(3.69%)

1.54B(4.51%)

1.45B(5.09%)

1.66B(5.87%)

1.12B(4.55%)

--(--)